Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cencora (GB:0HF3)
LSE:0HF3
Holding GB:0HF3?
Track your performance easily
0HF3 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$183.33 - $246.93
Previous Close$221.11
Volume256.00
Average Volume (3M)2.73K
Market Cap
$43.51B
Enterprise Value$45.07B
Total Cash (Recent Filing)$3.31B
Total Debt (Recent Filing)$4.73B
Price to Earnings (P/E)24.0
Beta0.25
Next Earnings
Nov 06, 2024EPS Estimate
$3.21Last Dividend Ex-Date
Aug 09, 2024Dividend Yield0.92%
Share Statistics
EPS (TTM)9.21
Shares Outstanding197,046,826
10 Day Avg. Volume555
30 Day Avg. Volume2,733
Standard Deviation0.06
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)46.79
Price to Sales (P/S)0.15
Price to Cash Flow (P/CF)4.40
P/FCF Ratio4.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.16
Enterprise Value/Gross Profit5.03
Enterprise Value/Ebitda12.31
Forecast
1Y Price Target
$265.50Price Target Upside20.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Cencora News
PremiumCompany Announcements
Cencora Announces EPS Forecast and Evernorth Contract Renewal
PremiumCompany Announcements
Cencora Enhances Governance and Executive Compensation StructuresBulls Say, Bears Say
Bulls Say
Contract ExtensionCencora extended its agreement with Evernorth Health through September 2029, highlighting its stability and long-term business relationships.
Financial PerformanceAnalyst reiterates an Outperform rating and increases the price target for COR, reflecting confidence in its financial performance.
Revenue Growth And ExpansionOneOncology's acquisition of the United Urology Group is a logical expansion, presenting a potential new customer win for COR's Specialty Practice GPO and boosting its long-term growth prospects.
Bears Say
Contractual RelationshipsCencora's relationship with its two largest customers, Walgreens and Cigna, are each evolving – which may act as an overhang.
Earnings OutlookRelatively lower EPS growth rate creates a weaker forward return profile given the elevated earnings multiple.
Market ExpectationsThe stock's current valuation reflects elevated expectations, needing more significant earnings beats to push shares higher.
---
Options Prices
Currently, No data available
---
Ownership Overview
10.45% Insiders
27.13% Mutual Funds
0.22% Other Institutional Investors
40.01% Public Companies and
Individual Investors
0HF3 FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest share price was $183.33 and its highest was $246.93 in the past 12 months.
What is Cencora’s market cap?
Currently, no data Available
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is Nov 06, 2024 which is in 26 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on Jul 31, 2024. The company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.217 by $0.123.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora pays a Quarterly dividend of $0.51 which represents an annual dividend yield of 0.92%. See more information on Cencora dividends here
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is $3.21.
How many shares outstanding does Cencora have?
Cencora has 197,046,830 shares outstanding.
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of $3.34 in its last earnings report, beating expectations of $3.217. Following the earnings report the stock price went up 2.118%.
Which hedge fund is a major shareholder of Cencora?
Among the largest hedge funds holding Cencora’s share is Antipodes Partners Ltd. It holds Cencora’s shares valued at 110M.
---
Cencora Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$265.50 (20.08% Upside)
$265.50 (20.08% Upside)
Blogger Sentiment
Bullish
GB:0HF3 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.1B over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.87%
12-Months-Change
Fundamentals
Return on Equity
230.42%
Trailing 12-Months
Asset Growth
9.15%
Trailing 12-Months
Company Description
Cencora
Cencora, Inc. engages provision of pharmaceutical products and business solutions that improve access
to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical
Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic
pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded
sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and
health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate
site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and
includes ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Chesterbrook, PA.
---
0HF3 Company Deck
---
0HF3 Earnings Call
Q3 2024
0:00 / 0:00
---
0HF3 Revenue Breakdown
87.62% Human Health
8.52% Alliance Healthcare
1.93% Other Healthcare Solutions
1.92% Animal Health
---
0HF3 Stock 12 Month Forecast
Average Price Target
$265.50
▲(20.08% Upside)
Technical Analysis
Best Analysts Covering 0HF3
1 Year
1 Year Success Rate
15/17 ratings generated profit
1 Year Average Return
+19.27%
reiterated a buy rating 8 months ago
Copying Kevin Caliendo's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +19.27% per trade.
---